Xu Zhenyu sold $145K of SOPH

Xu Zhenyu (Chief Scientific Officer) sold 20,000 shares of SOPHiA GENETICS SA (SOPH) at an average of $7.25 ($7.00–$7.48, $0.14M total) across 3 trades over 2026-08-05 to 2026-08-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Xu Zhenyu
Published Aug 7, 2026, 9:35 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SOPH
Neutral
medium confidence
Mentioned
$SOPH
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SOPHNeutralLow
01

Why it matters

The newest fact is the specific sale size, price range ($7.0043 to $7.4759), and that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider sale disclosure with limited direct implications for fundamentals, but it can marginally influence short-term sentiment.

03

What to watch

The filing does not state whether other insiders or the company also bought shares, nor does it provide context on total insider activity or option exercises.

Relevance 3/10Novelty 5/10Timing: filed Aug 7, after-hours SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for SOPHiA GENETICS SA, reported by its Chief Scientific Officer.

Company-level read

Ticker impact

$SOPHNeutralMedium confidence
Context

SOPHiA GENETICS CSO Xu Zhenyu sold about $145K of SOPH shares via a 10b5-1 plan, filing three trades from Aug 5-7.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around the filing date.

Evidence & confidence

The disclosure is an open-market sale by an officer under a pre-arranged 10b5-1 plan, with no accompanying operational or financial guidance changes in the text.

Market effects

No sector-wide signal; this is company-specific insider activity with no stated regulatory or clinical catalyst.

None indicated.

None indicated.

Counterpoint

Because it is a 10b5-1 plan, the sale may reflect liquidity planning rather than bearish expectations, so traders may ignore it beyond the immediate headline.

Key entities

  • SOPHiA GENETICS SA

    Company whose shares were sold by an officer under a 10b5-1 plan.

  • Xu Zhenyu

    Chief Scientific Officer who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September